{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-009115","form_type":"8-K","ticker":"CVRX","cik":"0001235912","company_name":"CVRx, Inc.","filed_at":"2025-02-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.141801+00:00","generated_at":"2026-05-27T03:19:50.187983+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CVRx Q4 2024 revenue $15.3M (+36% YoY); FY2025 revenue guidance $63-65M","bullets":["Q4 2024 total revenue $15.3M, +36% YoY; U.S. HF revenue $14.3M, +41% YoY (457 units vs 330).","FY2024 total revenue $51.3M, +31% YoY; net loss $60.0M ($2.65 per share) vs $41.2M in FY2023.","Active implanting centers grew to 223 as of Dec 31, 2024, up 25% from 178 a year earlier.","FY2025 guidance: total revenue $63-65M, gross margin 83-84%, operating expenses $100-104M.","Cash and cash equivalents $105.9M as of Dec 31, 2024; net cash used in ops/investing $40.5M in FY2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-009115","json":"https://secwatch.observer/filing/0001104659-25-009115.json","markdown":"https://secwatch.observer/filing/0001104659-25-009115.md","text":"https://secwatch.observer/filing/0001104659-25-009115.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1235912/000110465925009115/0001104659-25-009115-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1235912/000110465925009115/tm255369d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T03:19:50.187983+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}